Imovax Polio

Inactivated poliovirus vaccine, the active ingredient in Imovax Polio, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It induces immunity to prevent poliomyelitis caused by poliovirus types 1, 2 and 3 in children and adults, and is used in routine immunization programs.

GNH USA supplies Imovax Polio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with distribution aligned to EU regulatory standards and cold‑chain logistics for vaccine integrity, ensuring timely delivery and support.

Imovax Polio is an inactivated poliovirus vaccine used to prevent viral infection of the nervous system. - Poliomyelitis prevention: Provides active immunity that protects against disease caused by poliovirus types 1, 2 and 3. - Travel immunization: Safeguards travelers visiting regions where poliovirus transmission may occur. - Outbreak control: Supports public health campaigns to halt poliovirus spread during community outbreaks.

Injection of Imovax Polio may be associated with local and systemic reactions.

Common Side Effects: - Pain at injection site: mild to moderate discomfort where the vaccine is administered. - Redness or swelling: localized erythema that typically resolves within a few days. - Fever: transient elevation of body temperature, often low grade. - Headache or fatigue: general feeling of tiredness or mild headache after vaccination.

Serious or Rare Side Effects: - Allergic reaction (anaphylaxis): severe hypersensitivity requiring immediate medical attention. - Guillain‑Barré syndrome: rare neurological disorder characterized by muscle weakness. - Vaccine‑associated paralytic poliomyelitis: extremely rare occurrence of paralysis following vaccination.

Before administering Imovax Polio, consider the following safety measures. - Assess immunocompetence: avoid in severely immunocompromised patients. - Screen for allergy: defer if known hypersensitivity to any vaccine component. - Delay vaccination: postpone during acute febrile illness. - Pregnancy considerations: use only if benefits outweigh risks. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Imovax Polio may interact with other medical products; review the following.

Major Interactions (Avoid): - Live vaccines: avoid simultaneous administration with live attenuated vaccines. - Immunoglobulin therapy: postpone vaccination for at least 4 weeks after receipt. - Blood products: defer vaccination for 2 weeks after transfusion.

Moderate Interactions (Monitor Closely): - Immunosuppressive drugs: monitor antibody response for adequate protection. - Antipyretics: may mask fever post‑vaccination, use with caution. - Anticoagulants: monitor injection site for prolonged bleeding.